Outcomes for studies assessing the efficacy of hemostatic therapies in persons with congenital bleeding disorders
- 6 February 2021
- journal article
- review article
- Published by Wiley in Haemophilia
- Vol. 27 (2), 211-220
- https://doi.org/10.1111/hae.14247
Abstract
Introduction Management strategies and hemostatic treatments to achieve control of bleeding are relevant across many disease areas. Identification of primary outcomes for studies assessing hemostatic intervention was the objective of a National Heart, Lung and Blood Institute (NHLBI) sponsored multidisciplinary initiative. The aim of this report is to summarize the evidence reviewed, and the outcomes identified by the subgroup tasked to assess outcomes for inherited bleeding disorders. Methods The subgroup decided to focus on haemophilia, the prototypal congenital bleeding disorder and the one with the largest available body of evidence. MEDLINE, EMBASE and PsycINFO, The Cochrane Review, CINAHL, and Web of Science were searched for systematic and narrative reviews on outcomes used in haemophilia clinical trials. Three different clinical goals were identified as typical objectives of future research. Results Out of 1322 unique citations, 24 reviews published in the period 2002–2019 were included. We identified 113 outcome measures, categorized in 6 domains: health‐related quality of life (HRQoL), comorbidities and mortality, overall physical functioning and participation, bleeding and hemostasis, joint health, and costs and resource use. Three different clinical goals were identified as typical objectives of future research: Episodic ‘on demand’ replacement therapy, prevention of bleeding (Prophylaxis), and long‐term and overall impact of bleeding. For each of these scenarios, specific outcomes were recommended. Conclusions Primary outcomes for clinical trials assessing the efficacy of hemostatic treatment in achieving control, prevention and limiting long‐term consequences of bleeding in inherited bleeding disorders are suggested, and their strength and limitations discussed.Keywords
This publication has 70 references indexed in Scilit:
- Guidelines for the management of hemophiliaHaemophilia, 2012
- Interim data on long‐term efficacy, safety and tolerability of a plasma‐derived factor VIII concentrate in 109 patients with severe haemophilia AHaemophilia, 2012
- Utility of the Haemophilia Joint Health Score in study of episodically treated boys with severe haemophilia A and B in LithuaniaHaemophilia, 2010
- Mortality and causes of death in Italian persons with haemophilia, 1990–2007Haemophilia, 2010
- Challenges of defining reliable clinical surrogate end points in haemophilia trials: a critical reviewBlood Coagulation & Fibrinolysis, 2009
- Measuring patient‐reported outcomes in haemophilia clinical researchHaemophilia, 2009
- Prophylaxis versus Episodic Treatment to Prevent Joint Disease in Boys with Severe HemophiliaThe New England Journal of Medicine, 2007
- Short‐term oral corticosteroid therapy for acute haemarthrosis in haemophilia patients with high‐titre inhibitorsHaemophilia, 2006
- Hemophilia joint health score reliability studyHaemophilia, 2006
- A prospective randomized trial of high and standard dosages of recombinant factor VIIa for treatment of hemarthroses in hemophiliacs with inhibitorsJournal of Thrombosis and Haemostasis, 2006